Browse by category

The European Commission has granted final approval of a higher 7.2 mg maintenance dose of Wegovy (semaglutide) for adults who may need extra help losing weight. It is now approved in all 27 countries in the European Union. This gives doctors another option to help adults who need more weight loss after being on the 2.4 mg dose. The approval is based on a positive opinion from the European Medicines Agency’s scientific committee (CHMP) on 12 December 2025. The approval means t

Extended pouch gastric bypass (EP-RYGB) results in slightly better weight loss outcomes and similar health-related quality of life (HRQoL) compared to standard Roux-en-Y gastric bypass (S-RYGB) five to nine years postoperatively, according to researchers from the Netherlands. Anatomy of the surgical procedures. S-RYGB Standard Roux-en-Y gastric bypass, EP-RYGB Extended pouch Roux-en-Y gastric bypass The researchers hypothesised that a narrow longer pouch could lead to better

By 2030, nearly half of all American adults will have obesity, according to a study by researchers from the University of Virginia School of Medicine. In every single state, researchers expect at least 35% of adults to have a body mass index of 30 or higher, the threshold that defines obesity. That prediction may come as a shock, as weight loss medications like Wegovy and Zepbound become more popular and more affordable. The Centers for Disease Control and Prevention have bee

Just over one in 10 deaths from a wide range of infectious diseases can be attributed to obesity worldwide, according to a major study led by a University College London (UCL) researcher. The study also reported people with obesity face a 70% higher risk of hospitalisation or death from an infection than those of a healthy weight. Obesity can increase the risk posed by many different infectious diseases, from flu and COVID-19 to stomach bugs and urinary tract infections, and

Researchers at the University of Exeter have quantified the role of obesity in common long-term conditions, showing for the first time the effect of losing weight in preventing multiple diseases. "We've long known that certain diseases often occur together, and also that obesity increases the risk of many diseases. This largescale study is the first to use genetics to quantify the role of obesity in causing diseases to occur in the same individuals,” explained study lead, Pro

Bariatric surgery results in a sustained increase in the probability of being a paid employee from four months after surgery over the five-year follow-up period, leading to increased earnings, according to a study by UK researchers. The researchers noted that there is substantial evidence that living with obesity can affect an individual’s pay and employment however, there is little evidence on the impact of weight-management interventions, such as surgery, in improving labou

Researchers have found that people regain weight faster after quitting these GLP-1s  compared with after diet and exercise alone. Improvements in heart health and diabetes risk also tend to reverse within a few years. The results suggest long-term success may require more than medication alone. The findings call into question how durable these treatments really are. On average, individuals regained about 0.4 kilograms per month after stopping medication. Based on these trends

Higher rates of death among younger Australians from cardiovascular disease has been linked to being overweight or obese, a study by researchers at the University of Melbourne has reported. The study looked at premature overweight and obesity-related cardiovascular disease mortality for people aged between 35–74 years. Professor Tim Adair, a demographer in the Nossal Institute for Global Health at the University of Melbourne, used Australian Bureau of Statistics death certifi

Both biliopancreatic diversion with duodenal switch (BPD/DS) or single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) show comparable short-term outcomes when performed as revisional procedures following RYGB. Although overall perioperative complications did not differ between groups, the approximately 6% anastomotic leak rate observed in both cohorts highlights the greater complexity and risk inherent to revisional bariatric surgery relative to primary ope

Genentech announced positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP receptor agonist being developed for the treatment of obesity. The study found that once-weekly subcutaneous injections of CT-388 (titrated up to 24 mg) resulted in significant and clinically meaningful placebo-adjusted weight loss of 22.5% (efficacy estimand) without reaching a weight loss plateau at 48 weeks. CT-388 aims to reduce appetite and